T-cell receptor recognizing Tick-borne encephalitis virus-derived peptide–MHC-II complexes (TCR-TBEV-MHC-II)

The T-cell receptor (TCR) recognizing Tick-borne encephalitis virus (TBEV)-derived peptide–MHC-II complexes is a specialized protein complex found on the surface of CD4+ T lymphocytes. Its primary biological function is the specific recognition of TBEV-derived antigenic peptides, typically from the viral envelope (E) or non-structural (NS) proteins, which are presented by Major Histocompatibility Complex class II (MHC-II) molecules on the surface of professional antigen-presenting cells (Aberle et al., 2015). This recognition event is the cornerstone of the adaptive immune response to TBEV, initiating the activation and differentiation of T helper cells that coordinate B-cell antibody production and enhance the activity of other immune effectors (Schwaiger et al., 2014). In the context of disease, these TCRs are essential for clearing the virus and providing long-term immunity following infection or vaccination with inactivated TBEV vaccines. While not a target for traditional small-molecule drugs, these TCRs are the functional targets of TBEV vaccines and represent a focus for the development of TCR-engineered T-cell therapies aimed at treating severe or persistent flavivirus infections (Blom et al., 2015). Therapeutic challenges include the high degree of MHC polymorphism in the human population, which requires matching TCR specificity to the patient's HLA type, and the potential for off-target cross-reactivity with host proteins.

Other names

TBEV-specific TCRCD4+ T-cell receptor for TBEVMHC-II restricted TBEV TCRTick-borne encephalitis virus-specific T-cell receptor

Recognition of TBEV-derived peptides presented by MHC-II molecules on antigen-presenting cells, leading to the activation of CD4+ T helper cells and the orchestration of the adaptive immune response (Schwaiger et al., 2014; Blom et al., 2015).